Hims & Hers Super Bowl ad stirs up controversy with lawmakers

Mon, Feb 10, 2025, 8:34 AM

Hims & Hers Health (HIMS) stock moves a notch higher Monday morning after the company's weight-loss drug ad played during the Super Bowl. The commercial's airing raised concerns from health experts and US lawmakers over the exclusion of potential side effects tied to GLP-1 weight-loss treatments in the advertisement.

The Morning Brief's Seana Smith and Brad Smith report more on the controversy as Senators Dick Durbin (D-Il.) and Roger Marshall (R-KS) wrote a letter to the US Food and Drug Administration (FDA), citing that the commercial may "[risk] misleading patients."

To watch more expert insights and analysis on the latest market action, check out more Catalysts here.

This post was written by Luke Carberry Mogan.